Last Patient Completes Treatment in Phase 2b Study of Ameluz in Acne; Top-line Results Expected in Q1 2026
The final patient has completed treatment in Biofrontera Inc.’s Phase 2b clinical trial evaluating aminolevulinic acid hydrochloride (Ameluz) for the treatment of moderate-to-severe acne vulgaris (AV).